Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| 17.11 | |
| 17.04 | |
| - | |
| 17.81 | |
| 16.82 | |
| 3.5324-23.8599 | |
| 2 455 M | |
| 147 M | |
| 997 M | |
| -1.05 | |
| 1.974 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Each year, hundreds of stocks are delisted from U.S. exchanges. The path to delisting is usually long, and the signs are many. Generally speaking, delistings do not happen overnight. That means there ...
Novavax, Inc. (NASDAQ:NVAX) shareholders might be rather concerned because the share price has dropped 35% in the last month. But that doesn't change the fact that shareholders have received really go...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
